Twist Bioscience Analyst Ratings
Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target
Hims & Hers Health Analyst Ratings
Strong Market Reclaim and Innovative Pipeline Underpin Buy Rating for Tandem Diabetes Care
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)
Quest Diagnostics Analyst Ratings
JPMorgan Adjusts Price Target on Quest Diagnostics to $155 From $152
Tandem Diabetes Care Analyst Ratings
Insulet Analyst Ratings
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Hims & Hers Health Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Omnicell (OMCL), Tandem Diabetes Care (TNDM) and Amgen (AMGN)
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Hims & Hers Health's Strategic Growth in Weight Loss Market Warrants Buy Rating Despite Regulatory Risks
Doximity (DOCS) Receives a Hold From Truist Financial
Doximity's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Doximity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Zimmer Biomet Holdings (ZBH), Doximity (DOCS) and Arvinas Holding Company (ARVN)
Doximity (DOCS) Hold Rating Maintained Amid Balanced Growth Prospects and Market Uncertainty